Gan & Lee Pharmaceuticals 관리

관리 기준 확인 4/4

Gan & Lee Pharmaceuticals CEO는 Kai Du, Jul2020 에 임명되었습니다 의 임기는 4.33 년입니다. 는 CN¥ 25.22M 가치에 해당하는 회사 주식의 0.087% 직접 소유합니다. 25.22M. 경영진과 이사회의 평균 재임 기간은 각각 4.3 년과 4.6 년입니다.

주요 정보

Kai Du

최고 경영자

CN¥1.0m

총 보상

CEO 급여 비율	n/a
CEO 임기	4.3yrs
CEO 소유권	0.09%
경영진 평균 재임 기간	4.3yrs
이사회 평균 재임 기간	4.6yrs

최근 관리 업데이트

Recent updates

Shareholders In Gan & Lee Pharmaceuticals (SHSE:603087) Should Look Beyond Earnings For The Full Story

Sep 04

Analysts Just Shipped A Sizeable Upgrade To Their Gan & Lee Pharmaceuticals. (SHSE:603087) Estimates

Apr 29

Some Confidence Is Lacking In Gan & Lee Pharmaceuticals.'s (SHSE:603087) P/S

Mar 01

CEO

Kai Du (47 yo)

4.3yrs

테뉴어

CN¥1,041,900

보상

Mr. Kai Du is General Manager of Gan & Lee Pharmaceuticals. since July 20, 2020 and has been its Director since April 26, 2019.

리더십 팀

이름	위치	테뉴어	보상	소유권
Gan Zhongru	Founder & Chairman	26.8yrs	CN¥457.20k	35.48% CN¥ 10.3b
Kai Du	GM & Director	4.3yrs	CN¥1.04m	0.087% CN¥ 25.2m
Cheng Sun	CFO & Deputy GM	4.3yrs	CN¥695.20k	0.089% CN¥ 25.7m
Wei Chen	Deputy GM & Director	less than a year	CN¥892.20k	0.087% CN¥ 25.2m
Weiqiang Song	Deputy GM & Director	8.8yrs	CN¥960.50k	0.087% CN¥ 25.2m
Rong Zou	Secretary	6.9yrs	CN¥695.00k	0.087% CN¥ 25.2m
Cheng Xing	Deputy General Manager	4.3yrs	CN¥752.80k	0.087% CN¥ 25.2m
Zifei Yuan	Deputy General Manager	4.3yrs	CN¥710.50k	0.087% CN¥ 25.2m
Zhi Li	Deputy General Manager	less than a year	데이터 없음	데이터 없음

4.3yrs

평균 재임 기간

42yo

평균 연령

경험이 풍부한 관리: 603087 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Gan Zhongru	Founder & Chairman	26.8yrs	CN¥457.20k	35.48% CN¥ 10.3b
Kai Du	GM & Director	5.6yrs	CN¥1.04m	0.087% CN¥ 25.2m
Wei Chen	Deputy GM & Director	3.2yrs	CN¥892.20k	0.087% CN¥ 25.2m
Weiqiang Song	Deputy GM & Director	9.2yrs	CN¥960.50k	0.087% CN¥ 25.2m
Jiao Jiao	Director	3.7yrs	CN¥1.04m	0.045% CN¥ 13.1m
Lei Yin	Director	3.7yrs	CN¥897.10k	0.020% CN¥ 5.8m
Yanqing He	Independent Director	5.6yrs	CN¥72.00k	데이터 없음
Guojun Zheng	Independent Director	5.6yrs	CN¥72.00k	데이터 없음
Yi Wang	Supervisor	3.7yrs	데이터 없음	데이터 없음
Tao Zhang	Chairman of the Board of Supervisors	3.2yrs	데이터 없음	데이터 없음
Jiaxin Wang	Supervisor	5.6yrs	데이터 없음	데이터 없음
Zengyi Chang	Independent Director	2.5yrs	CN¥72.00k	데이터 없음

4.6yrs

평균 재임 기간

44.5yo

평균 연령

경험이 풍부한 이사회: 603087 의 이사회는 경험(평균 재직 기간 4.6 년)으로 간주됩니다.

Gan & Lee Pharmaceuticals 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Gan & Lee Pharmaceuticals., Annual General Meeting, May 16, 2024

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Gan & Lee Pharmaceuticals. to Report Q3, 2024 Results on Oct 23, 2024

Investor sentiment improves as stock rises 18%

Gan & Lee Pharmaceuticals. (SHSE:603087) announces an Equity Buyback for CNY 300 million worth of its shares.

Shareholders In Gan & Lee Pharmaceuticals (SHSE:603087) Should Look Beyond Earnings For The Full Story

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Gan & Lee Pharmaceuticals. to Report First Half, 2024 Results on Aug 29, 2024

Price target increased by 7.8% to CN¥62.50

Analysts Just Shipped A Sizeable Upgrade To Their Gan & Lee Pharmaceuticals. (SHSE:603087) Estimates

Gan & Lee Pharmaceuticals., Annual General Meeting, May 16, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Gan & Lee Pharmaceuticals. to Report Q1, 2024 Results on Apr 25, 2024

Some Confidence Is Lacking In Gan & Lee Pharmaceuticals.'s (SHSE:603087) P/S

Gan & Lee Pharmaceuticals. to Report Fiscal Year 2023 Results on Apr 25, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.39 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.55 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.09 (vs CN¥0.20 in 1Q 2022)

Gan & Lee Pharmaceuticals.(XSSC:603087) dropped from FTSE All-World Index (USD)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.39 loss per share (vs CN¥0.90 profit in 3Q 2021)

Gan & Lee Pharmaceuticals. announced that it expects to receive CNY 813.6 million in funding

Investor sentiment improved over the past week

Second quarter 2022 earnings released: CN¥0.55 loss per share (vs CN¥0.32 profit in 2Q 2021)

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Gan & Lee Pharmaceuticals Co., Ltd. Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18

Third quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.70 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.34 in 2Q 2020)

Investor sentiment deteriorated over the past week

Gan & Lee Pharmaceuticals Co., Ltd. Announces Positive Phase 1 Clinical Trial Results at the 81st Scientific Sessions of the American Diabetes Association

First quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.24 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥2.31 (vs CN¥2.31 in FY 2019)

New 90-day low: CN¥121

FDA Grants Fast Track Designation for Gan & Lee Pharmaceuticals Co., Ltd.'s GLR2007, for the Treatment of Patients with Glioblastoma

Investor sentiment improved over the past week

New 90-day high: CN¥174

Investor sentiment improved over the past week

New 90-day high: CN¥136

New 90-day low: CN¥115

Third quarter earnings released

Earnings released

Gan & Lee Pharmaceutical, Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Gan & Lee Pharmaceutical, Ltd. announced that it has received funding from Hillhouse Capital Management, Ltd.

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령